1910 GTM brain

category

market profile

• text: Drug discovery teams face data, compute and experimental validation bottlenecks when adopting AI.
• text: 1910 combines multimodal data, AI models and high-throughput lab automation for therapeutic discovery.

personas

• title: Head of pharmaceutical discovery or R&D
  pains:

  • Expensive, slow cycles of compound design and biological testing
  • Need to prioritize promising small and large molecule candidates
• title: Head of computational biology or AI
  pains:

  • Insufficient high-quality biological data for training
  • Difficulty combining models, compute and wet-lab validation in a usable workflow

icp

• text: Biopharma and biotech organizations with active small or large molecule discovery programs.
• text: Discovery teams seeking custom AI infrastructure and scientific collaboration rather than a generic chatbot.

message pillars

• text: Apply one platform to multiple therapeutic modalities.
• text: Connect AI with experimental throughput.
• text: Co-engineer discovery modules for the partner's organization.

objections

• objection: Can a model predict molecules that work experimentally?
  response: Evaluate model performance on a defined target and assay using 1910's wet-lab validation approach.
• objection: Will this fit our existing scientific workflow?
  response: Discuss co-engineered data, model, compute and interactive tool components against the team's requirements.

competitors

• name: Generate Biomedicines
  why: AI-enabled therapeutic discovery company.
• name: Nabla Bio
  why: AI-driven drug design and biopharma partnerships.
• name: Atomic AI
  why: AI drug discovery platform focused on RNA biology.

influencers

• name: Jen Nwankwo
  url: https://www.1910.ai/press-releases/microsoft-and-1910-partner-to-build-the-infrastructure-layer-for-drug-discovery-and-development-using-ai-and-high-performance-computing
  why: Founder and CEO explaining 1910's AI and wet-lab approach.

keywords

• AI drug discovery platform
• multimodal drug discovery
• small molecule discovery AI
• protein therapeutics discovery
• AI wet lab automation
• biopharma AI partnership

voice

• Scientific
• Ambitious
• Technology-forward

signals

• text: A new discovery program needing molecular design and experimental validation is a potential partnering trigger.
• text: Investment in computational biology or AI transformation indicates potential infrastructure demand.

stack

• Microsoft high-performance computing partnership

pricing

motion

channels

• strategic partnerships
• scientific publications
• press
• LinkedIn

confidence

Founders

• name: Jen Asher
  title: Founder/CEO
  role: CEO
  bio: Founder & CEO @ 1910 Genetics